0001193125-17-045992.txt : 20170216 0001193125-17-045992.hdr.sgml : 20170216 20170216091404 ACCESSION NUMBER: 0001193125-17-045992 CONFORMED SUBMISSION TYPE: SC TO-T/A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20170216 DATE AS OF CHANGE: 20170216 GROUP MEMBERS: KIKU MERGER CO., INC. GROUP MEMBERS: TPA HOLDING I, INC. GROUP MEMBERS: TPA HOLDING II, INC. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ARIAD PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000884731 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 223106987 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC TO-T/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-48751 FILM NUMBER: 17616601 BUSINESS ADDRESS: STREET 1: 125 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 6174940400 MAIL ADDRESS: STREET 1: 125 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ARIAD PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000884731 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 223106987 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-48751 FILM NUMBER: 17616602 BUSINESS ADDRESS: STREET 1: 125 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 6174940400 MAIL ADDRESS: STREET 1: 125 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: TAKEDA PHARMACEUTICAL CO LTD CENTRAL INDEX KEY: 0001395064 IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: SC TO-T/A BUSINESS ADDRESS: STREET 1: 1-1, DOSCHOMACHI 4-CHOME CITY: CHUO-KU, OSALCA 540-8645 STATE: M0 ZIP: 00000 MAIL ADDRESS: STREET 1: 1-1, DOSCHOMACHI 4-CHOME CITY: CHUO-KU, OSALCA 540-8645 STATE: M0 ZIP: 00000 SC TO-T/A 1 d318878dsctota.htm AMENDMENT NO. 5 TO SC TO-T Amendment No. 5 to SC TO-T

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE TO

(RULE 14D-100)

Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1)

of the Securities Exchange Act of 1934

(Amendment No. 5)

 

 

ARIAD Pharmaceuticals, Inc.

(Name of Subject Company)

KIKU MERGER CO., INC.

(Offeror)

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(Parent of Offeror)

(Names of Filing Persons)

 

 

Common stock, par value $0.001 per share

(Title of Class of Securities)

04033A100

(CUSIP Number of Class of Securities)

James Kehoe

Takeda Pharmaceutical Company Limited

12-10, Nihonbashi 2-chome, Chuo-ku, Tokyo 103-8668

Tel: +81 3 3278-2111

(Name, Address and Telephone Number of Person Authorized to Receive Notices and

Communications on Behalf of Filing Persons)

With a copy to:

Paul J. Shim

Kimberly R. Spoerri

Cleary Gottlieb Steen & Hamilton LLP

One Liberty Plaza

New York, New York 10006

(212) 225-2000

 

 

CALCULATION OF FILING FEE

 

Transaction Valuation*   Amount of Filing Fee**
$4,898,591,936   $567,746.81
* Calculated solely for purposes of determining the filing fee. The calculation of the transaction value is determined by adding the sum of (i) 194,580,850 shares of common stock, par value $0.001 per share, of ARIAD Pharmaceuticals, Inc. multiplied by the offer price of $24.00 per share, (ii) 9,236,071 shares subject to issuance pursuant to granted and outstanding stock options multiplied by $15.11 (which is calculated by subtracting $8.89, the weighted average price of all outstanding stock options, from the offer price of $24.00 per share), (iii) 1,901,731 shares subject to issuance pursuant to granted and outstanding restricted stock units multiplied by the offer price of $24.00 per share, (iv) 1,788,540 shares subject to issuance pursuant to granted and outstanding performance stock units at the greater of (A) the target level of performance for each such performance stock unit and (B) the estimated actual level of performance determined as of January 13, 2017, multiplied by the offer price of $24.00 per share, and (v) 22,000 shares estimated to be subject to outstanding purchase rights under ARIAD’s 2007 Employee Stock Purchase Plan multiplied by the offer price of $24.00 per share. The calculation of the filing fee is based on information provided by ARIAD as of January 13, 2017.
** The filing fee was calculated in accordance with Rule 0-11 under the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory No. 1 for Fiscal Year 2017, issued August 31, 2016, by multiplying the transaction valuation by 0.0001159.

 

☒  Check box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.

 

Amount Previously Paid: $567,746.81

Form or Registration No: Schedule TO

    Filing Party: Kiku Merger Co., Inc. and Takeda
Pharmaceutical Company Limited
   Date Filed: January 19, 2017

 

☐  Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

 

  ☒  third-party tender offer subject to Rule 14d-1.
  ☐  issuer tender offer subject to Rule 13e-4.
  ☐  going-private transaction subject to Rule 13e-3.
  ☒  amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer:  ☒

 

 

 

CUSIP No. 04033A100   13D  

 

  1   

NAMES OF REPORTING PERSONS

 

Takeda Pharmaceutical Company Limited

  2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

(a)  ☐        (b)  ☐

 

  3  

SEC USE ONLY

 

  4  

SOURCE OF FUNDS (see instructions)

 

OO (See Item 3)

  5  

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)  ☐

 

  6  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Japan

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 

      7    

SOLE VOTING POWER

 

-0-

     8   

SHARED VOTING POWER

 

100

     9   

SOLE DISPOSITIVE POWER

 

-0-

   10   

SHARED DISPOSITIVE POWER

 

100

11  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

100

12  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)  ☐

 

13  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

 

100%

14  

TYPE OF REPORTING PERSON

 

CO

 

CUSIP No. 04033A100   13D  

 

  1   

NAMES OF REPORTING PERSONS

 

Kiku Merger Co., Inc.

  2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

(a)  ☐        (b)  ☐

 

  3  

SEC USE ONLY

 

  4  

SOURCE OF FUNDS (see instructions)

 

OO (See Item 3)

  5  

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)  ☐

 

  6  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 

      7    

SOLE VOTING POWER

 

-0-

     8   

SHARED VOTING POWER

 

100

     9   

SOLE DISPOSITIVE POWER

 

-0-

   10   

SHARED DISPOSITIVE POWER

 

100

11  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

100

12  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)  ☐

 

13  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

 

100%

14  

TYPE OF REPORTING PERSON

 

CO

 

CUSIP No. 04033A100   13D  

 

  1   

NAMES OF REPORTING PERSONS

 

TPA Holding I, Inc.

  2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

(a)  ☐        (b)  ☐

 

  3  

SEC USE ONLY

 

  4  

SOURCE OF FUNDS (see instructions)

 

OO (See Item 3)

  5  

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)  ☐

 

  6  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 

      7    

SOLE VOTING POWER

 

-0-

     8   

SHARED VOTING POWER

 

100

     9   

SOLE DISPOSITIVE POWER

 

-0-

   10   

SHARED DISPOSITIVE POWER

 

100

11  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

100

12  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)  ☐

 

13  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

 

100%

14  

TYPE OF REPORTING PERSON

 

CO

 

CUSIP No. 04033A100   13D  

 

  1   

NAMES OF REPORTING PERSONS

 

TPA Holding II, Inc.

  2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

(a)  ☐        (b)  ☐

 

  3  

SEC USE ONLY

 

  4  

SOURCE OF FUNDS (see instructions)

 

OO (See Item 3)

  5  

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)  ☐

 

  6  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 

      7    

SOLE VOTING POWER

 

-0-

     8   

SHARED VOTING POWER

 

100

     9   

SOLE DISPOSITIVE POWER

 

-0-

   10   

SHARED DISPOSITIVE POWER

 

100

11  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

100

12  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)  ☐

 

13  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

 

100%

14  

TYPE OF REPORTING PERSON

 

CO

 

This Amendment No. 5 (this “Amendment”) amends and supplements the Tender Offer Statement on Schedule TO filed by Kiku Merger Co., Inc., a Delaware corporation (“Purchaser”) and a wholly-owned indirect subsidiary of Takeda Pharmaceutical Company Limited, a corporation organized under the laws of Japan (“Takeda”), with the Securities and Exchange Commission on January 19, 2017 (together with any subsequent amendments and supplements thereto, including this Amendment, the “Schedule TO”). The Schedule TO relates to the tender offer by Purchaser for all of the outstanding shares of common stock, par value $0.001 per share (“Shares”), of ARIAD Pharmaceuticals, Inc., a Delaware corporation (“ARIAD”), at a price of $24.00 per Share in cash, net of applicable withholding taxes and without interest, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated January 19, 2017 (the “Offer to Purchase”), a copy of which is attached as Exhibit (a)(1)(A), and in the related letter of transmittal (the “Letter of Transmittal”, a copy of which is attached as Exhibit (a)(1)(B), and which, together with the Offer to Purchase and other related materials, as each may be amended or supplemented from time to time, collectively constitute the “Offer”).

All the information set forth in the Offer to Purchase, including Schedule I thereto, is incorporated by reference herein in response to Items 1 through 9 and Item 11 of this Schedule TO, and is supplemented by the information specifically provided in this Amendment.

Capitalized terms used but not defined in this Amendment shall have the meanings assigned to such terms in the Schedule TO.

Items 1 through 9 and Item 11.

The Offer to Purchase and Items 1 through 9 and Item 11 of the Schedule TO, to the extent such Items incorporate by reference the information contained in the Offer to Purchase, are hereby amended and supplemented as set forth below:

“The Offer and withdrawal rights expired as scheduled at 11:59 p.m., Eastern time, on Wednesday, February 15, 2017. The Depositary has indicated that, as of the Expiration Time, a total of 158,558,628 Shares (excluding Shares with respect to which notices of guaranteed delivery were delivered but which Shares were not yet delivered) have been validly tendered and not validly withdrawn pursuant to the Offer, representing approximately 81.4% of the outstanding Shares as of the Expiration Time. The number of Shares validly tendered and not properly withdrawn pursuant to the Offer satisfies the Minimum Tender Condition. All conditions to the Offer having been satisfied or waived, Purchaser has accepted for payment and will promptly pay for all such Shares in accordance with the Offer.

As a result of its acceptance of the Shares tendered in the Offer, Purchaser acquired a sufficient number of Shares to complete the Merger without a vote of the stockholders of the company pursuant to Section 251(h) of the DGCL. Accordingly, on February 16, 2017, Parent and Purchaser effected the Merger pursuant to Section 251(h) of the DGCL. Pursuant to the Merger Agreement, in the Merger, each Share that was issued and outstanding immediately prior to the Effective Time (other than Shares (i) owned by Parent, Purchaser or any other direct or indirect wholly-owned subsidiary of Parent immediately prior to the Effective Time, (ii) owned by the Company or any direct or indirect wholly-owned subsidiary of the Company or held in the Company’s treasury or (iii) held by a holder who is entitled to appraisal and who has properly exercised appraisal rights for such Shares in accordance with Section 262 of the DGCL) was converted automatically into the right to receive $24.00 in cash, net of applicable withholding taxes and without interest (which is the same amount per Share paid in the Offer). Following the Merger, all Shares will be delisted from NASDAQ and deregistered under the Exchange Act.

On February 16, 2017, Takeda issued a press release announcing the expiration and successful completion of the Offer and the consummation of the Merger. A copy of the press release issued by Takeda is attached hereto as Exhibit (a)(5)(A) and is incorporated herein by reference.”

Item 12. Exhibits

Item 12 of the Schedule TO is amended and supplemented by adding the following:

 

Exhibit
No.

  

Description

(a)(5)(A)   Press Release, dated February 16, 2017.

SIGNATURES

After due inquiry and to the best of their knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

 

TAKEDA PHARMACEUTICAL COMPANY LIMITED
By:  

/s/ Christophe Weber

Name:   Christophe Weber
Title:   President and Chief Executive Officer

KIKU MERGER CO., INC.

By:  

/s/ Fabien Dubois

Name:   Fabien Dubois
Title:   Treasurer

Dated: February 16, 2017

EXHIBIT INDEX

 

Exhibit

No.

  

Description

(a)(1)(A)   Offer to Purchase, dated January 19, 2017.*
(a)(1)(B)   Letter of Transmittal.*
(a)(1)(C)   Notice of Guaranteed Delivery.*
(a)(1)(D)   Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.*
(a)(1)(E)   Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.*
(a)(1)(F)   Summary Advertisement as published in The New York Times on January 19, 2017.*
(a)(1)(G)   Press Release, dated January 9, 2017 (incorporated by reference to Exhibit 99.1 to the Schedule TO-C filed by Takeda Pharmaceutical Company Limited with the U.S. Securities and Exchange Commission on January 9, 2017).*
(a)(1)(H)   Press Release, dated January 9, 2017, as filed with the Tokyo Stock Exchange (incorporated by reference to Exhibit 99.2 to the Schedule TO-C filed by Takeda Pharmaceutical Company Limited with the U.S. Securities and Exchange Commission on January 9, 2017).*
(a)(1)(I)   Tweet from January 9, 2017, by Takeda Oncology (@TakedaOncology) (incorporated by reference to Exhibit 99.3 to the Schedule TO-C filed by Takeda Pharmaceutical Company Limited with the U.S. Securities and Exchange Commission on January 9, 2017).*
(a)(1)(J)   LinkedIn posting from January 9, 2017, by Takeda Oncology (incorporated by reference to Exhibit 99.4 to the Schedule TO-C filed by Takeda Pharmaceutical Company Limited with the U.S. Securities and Exchange Commission on January 9, 2017).*
(a)(1)(K)   Facebook posting from January 9, 2017, by Takeda Oncology (incorporated by reference to Exhibit 99.5 to the Schedule TO-C filed by Takeda Pharmaceutical Company Limited with the U.S. Securities and Exchange Commission on January 9, 2017).*
(a)(1)(L)   Letter, dated January 9, 2017, from Christophe Weber to employees of ARIAD Pharmaceuticals, Inc. (incorporated by reference to Exhibit 99.6 to the Schedule TO-C filed by Takeda Pharmaceutical Company Limited with the U.S. Securities and Exchange Commission on January 9, 2017).*
(a)(1)(M)   Excerpts from presentation at J.P. Morgan Healthcare Conference 2017, dated January 9, 2017 (incorporated by reference to Exhibit 99.1 to the Schedule TO-C filed by Takeda Pharmaceutical Company Limited with the U.S. Securities and Exchange Commission on January 10, 2017).*
(a)(1)(N)   Presentation Accompanying Conference Call, dated January 9, 2017 (incorporated by reference to Exhibit 99.2 to the Schedule TO-C filed by Takeda Pharmaceutical Company Limited with the U.S. Securities and Exchange Commission on January 10, 2017).*
(a)(1)(O)   Excerpts from transcript of presentation at J.P. Morgan Healthcare Conference 2017, dated January 9, 2017, link available on Takeda’s external website (incorporated by reference to Exhibit 99.1 to the Schedule TO-C filed by Takeda Pharmaceutical Company Limited with the U.S. Securities and Exchange Commission on January 11, 2017).*
(a)(1)(P)   Transcript of Conference Call, dated January 9, 2017, available on Takeda’s external website (incorporated by reference to Exhibit 99.2 to the Schedule TO-C filed by Takeda Pharmaceutical Company Limited with the U.S. Securities and Exchange Commission on January 11, 2017).*

(a)(1)(Q)   Press Release, dated January 19, 2017.*
(a)(1)(R)   Press Release, dated February 1, 2017.*
(a)(1)(S)   Excerpts from presentation accompanying Q3 Earnings Conference Call, dated February 1, 2017, available on Takeda’s external website.*
(a)(1)(T)   Excerpts from transcript of Q3 Earnings Conference Call, dated February 1, 2017, audio available on Takeda’s external website.*
(a)(5)(A)   Press Release, dated February 16, 2017.
(b)(1)   Loan Agreement, dated as of February 8, 2017, by and between Takeda Pharmaceutical Company Limited, as Borrower, and Sumitomo Mitsui Banking Corporation, as Lender.*
(b)(2)   Loan Agreement, dated as of February 8, 2017, by and between Takeda Pharmaceutical Company Limited, as Borrower, and The Bank of Tokyo-Mitsubishi UFJ, Ltd., as Lender.*
(d)(1)   Agreement and Plan of Merger, dated as of January 8, 2017 between ARIAD Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited and Kiku Merger Co., Inc. (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by ARIAD Pharmaceuticals, Inc. with the U.S. Securities and Exchange Commission on January 10, 2017).*
(d)(2)   Confidentiality Agreement, dated as of December 18, 2016, between ARIAD Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited.*
(d)(3)   Exclusivity Agreement, dated as of December 26, 2016, among ARIAD Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited.*
(d)(4)   Form of Tender and Support Agreement (incorporated by reference to Exhibit 99.3 to the Current Report on Form 8-K filed by ARIAD Pharmaceuticals, Inc. with the U.S. Securities and Exchange Commission on January 10, 2017).*
(g)   None.
(h)   None.

 

* Previously filed.
EX-99.(A)(5)(A) 2 d318878dex99a5a.htm EX-99.(A)(5)(A) EX-99.(a)(5)(A)

Exhibit (a)(5)(A)

 

LOGO

Takeda Completes Acquisition of ARIAD Pharmaceuticals, Inc.

– Significantly Enhances Takeda’s Global Oncology Portfolio –

– Accretive to FY2018 Underlying Core Earnings –

– Reinforces Takeda’s Commitment to Developing Medicines for Patients Living with Cancer –

Cambridge, Mass. and Osaka, Japan, February 16, 2017 – Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today announced the completion of its acquisition of ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) (“ARIAD”) for $24.00 per share in cash.

“We are very pleased to have completed the acquisition of ARIAD Pharmaceuticals. The addition of ARIAD’s innovative targeted therapies and research and development capabilities strengthens and diversifies our oncology business, positioning Takeda for sustainable long-term growth in this priority therapeutic area,” said Christophe Weber, president and chief executive officer of Takeda. “We are particularly excited by the global potential of brigatinib, an investigational drug product, which we believe will become a best-in-class ALK inhibitor for non-small cell lung cancer with the potential to achieve peak annual sales of over $1 billion. We are also impressed with the swiftness and agility of Takeda and ARIAD employees as they have planned for a successful integration while remaining focused on strategic goals. This bodes very well for the future of our combined business, and we look forward to building on this strong start to maximize the benefit of Iclusig® (ponatinib) and potential of brigatinib for cancer patients.”

“The acquisition of ARIAD is transformational for Takeda Oncology. Iclusig enhances our strong position in hematology in the U.S., and brigatinib has the potential to broaden our solid tumor franchise globally,” said Christophe Bianchi, president of Takeda Oncology. “There is a strong cultural fit between our two companies, with a shared mission to advance innovative therapies to improve the lives of patients with cancer. We have been working together over the past month to plan for a smooth integration of our businesses and we will work closely with regulatory authorities on our brigatinib market authorization submissions.”

Takeda continues to expect the transaction to be accretive to Underlying Core Earnings by FY2018. Strong revenue growth and synergy savings will offset increased sales and marketing costs for the anticipated brigatinib launch.

Tender Offer Details

Takeda completed the acquisition through a tender offer and subsequent merger of ARIAD with Kiku Merger Co., Inc., a wholly owned subsidiary of Takeda Pharmaceuticals U.S.A. ARIAD is now an indirect wholly owned subsidiary of Takeda.

The tender offer for all of the outstanding shares of ARIAD common stock expired as scheduled, immediately following the offer’s expiration time of 11:59 p.m., Eastern Time, on February 15, 2017. Computershare Trust Company, N.A., the depositary and paying agent for the tender offer, has advised Takeda that 158,558,628 shares of ARIAD common stock were tendered, representing approximately 81.4% of the shares outstanding. All of the conditions to the tender offer having been satisfied, Takeda’s indirect wholly owned subsidiary Kiku Merger Co., Inc. has accepted for payment and will promptly pay for all shares tendered. The transaction will be funded by approximately $3.5 billion of new debt and the remainder from existing cash. Takeda is expected to remain investment grade and the transaction has no impact on Takeda’s dividend policy.

On February 16, 2017, Takeda completed its acquisition of ARIAD through the merger of Kiku Merger Co., Inc. with ARIAD without a vote of ARIAD’s shareholders pursuant to Section 251(h) if the Delaware General Corporation Law. As a result of the merger, ARIAD became an indirect wholly owned subsidiary of Takeda. In connection with the merger, all ARIAD shares not purchased in the tender offer have been converted into the right to receive $24.00 per share in cash, without interest (less any required withholding taxes), the same amount paid for all shares validly tendered and not validly withdrawn in the tender offer. ARIAD common stock will cease to be traded on the NASDAQ Global Select Market.

Evercore Partners acted as financial advisor and Cleary Gottlieb Steen & Hamilton LLP acted as legal advisor to Takeda. J.P. Morgan Securities LLC, Goldman, Sachs & Co. and Lazard acted as financial advisors and Paul, Weiss, Rifkind, Wharton & Garrison LLP acted as legal advisor to ARIAD.

About Takeda Pharmaceutical Company

Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. Additional information about Takeda is available through its corporate website, www.Takeda.com.

Please see ICLUSIG® (ponatinib) full Prescribing Information, including Boxed Warning.

 

 

Media and Investor Contacts

Takeda Investor Contact

Noriko Higuchi

noriko.higuchi@Takeda.com

+81 (0) 3-3278-2306

Takeda Media outside Japan

Shawn Goodman

shawn.goodman@Takeda.com

+1-415-250-0766

Japanese Media

Tsuyoshi Tada

tsuyoshi.tada@Takeda.com

+81 (0) 3-3278-2417

 

2

Kal Goldberg, Finsbury

kal.goldberg@finsbury.com

+1-646-805-2005

Chris Ryall, Finsbury

chris.ryall@finsbury.com

+1-646-805-2078

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements. When used in this press release, the words “can,” “will,” “believes,” “intends,” “expects,” “is expected,” similar expressions and any other statements that are not historical facts are intended to identify those assertions as forward-looking statements. Such statements are based on a number of assumptions that could ultimately prove inaccurate, and are subject to a number of risks. Neither Takeda nor ARIAD assumes any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, unless required by law.

###

 

3

GRAPHIC 3 g318878g48u92.jpg GRAPHIC begin 644 g318878g48u92.jpg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�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end